Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Pulmonary Disease COPD Clear all
Completed Not applicable Interventional

Feasibility of a Multi Component Intervention in Patients With Severe Dyspnea and Obesity

NCT03836547
View directory record Official record
Conditions
COPD, Emphysema, Lung Diseases
Interventions
Coaching and Weight Loss for patients with dyspnea, Active Control
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 17, 2026, 11:16 PM EDT
Completed Not applicable Interventional

Electronic Cigarettes as a Harm Reduction Strategy Among Patients With COPD

NCT04465318
View directory record Official record
Conditions
COPD
Interventions
E-cigarette (EC), Nicotine Replacement Therapy (NRT), Smoking Harm Reduction Counseling Sessions
Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 75 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 17, 2026, 11:16 PM EDT
Recruiting Phase 4 Interventional

Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

NCT07133880
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 17, 2026, 11:16 PM EDT
Completed Phase 2 Interventional Results available

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01587079
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT003, PT001, PT005, Tiotropium inhalation powder
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
19
States / cities
Glendale, Arizona • Rancho Mirage, California • Waterbury, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 17, 2026, 11:16 PM EDT
Terminated Phase 4 Interventional Results available

Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease

NCT01554488
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea
Interventions
Inhaled Fluticasone Propionate
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 17, 2026, 11:16 PM EDT
Completed Phase 4 Interventional Results available

Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

NCT00633217
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Propionate/Salmeterol DISKUS 250/50mcg, Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Jasper, Alabama • Mobile, Alabama • Lafayette, Louisiana + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 17, 2026, 11:16 PM EDT
Recruiting Phase 2 Interventional

Pulmonary Hypertension SOLAR

NCT04778046
View directory record Official record
Conditions
Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
Interventions
Hyperpolarized 129Xe
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 17, 2026, 11:16 PM EDT
Completed Not applicable Interventional

Reducing Disparities in the Quality of Advance Care Planning for Older Adults

NCT03516994
View directory record Official record
Conditions
Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease, Interstitial Lung Disease, Amyotrophic Lateral Sclerosis, End Stage Liver Disease, End Stage Renal Disease, Diabetes Complications
Interventions
Respecting Choices First Steps, Five Wishes Form
Behavioral
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Atlanta, Georgia • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 17, 2026, 11:16 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01551888
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Aclidinium/formoterol 400/12μg, Formoterol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Oct 17, 2026, 11:16 PM EDT
Completed Not applicable Interventional

A Home-based Intervention to Promote Mindful Breathing Awareness Through Pursed-lip Breathing Training for COPD Patients

NCT03814980
View directory record Official record
Conditions
COPD, Emphysema
Interventions
mindful breathing application, application on a computer tablet
Behavioral · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 17, 2026, 11:16 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 17, 2026, 11:16 PM EDT
Completed Phase 3 Interventional

Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients

NCT00274508
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium bromide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 17, 2026, 11:16 PM EDT
Completed No phase listed Observational

Replication of the IMPACT COPD Trial in Healthcare Claims Data

NCT05062304
View directory record Official record
Conditions
COPD
Interventions
Fluticasone Furoate-Vilanterol Trifenatate, Furoate-umeclidinium-vilanterol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 120 Years
Enrollment
17,281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 17, 2026, 11:16 PM EDT
Completed No phase listed Observational Results available

A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

NCT05127304
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Trelegy Ellipta, Stiolto Respimat, Furoate/Umeclidinium/Vilanterol, Tiotropium Bromide/Olodaterol
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
11,316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 17, 2026, 11:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Tracheal Mechanics During Bronchoscopy

NCT00536315
View directory record Official record
Conditions
Tracheomalacia, Tracheobronchomalacia
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years and older
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 17, 2026, 11:16 PM EDT
Completed Not applicable Interventional Results available

Mechanistic Effects of Health Coaching to Reduce Chronic Obstructive Pulmonary Disease (COPD) Hospitalizations

NCT03837847
View directory record Official record
Conditions
COPD, Emphysema
Interventions
Health Coaching Calls, Control
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 17, 2026, 11:16 PM EDT
Recruiting No phase listed Observational

Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities

NCT07748858
View directory record Official record
Conditions
Cardiovascular, Comorbidity, Diabetes, Inflammatory Joint Diseases, Chronic Kidney Diease, Chronic Obstructive Pulmonary Disease (COPD), Cardiovascular Disease
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 17, 2026, 11:16 PM EDT
Completed Not applicable Interventional Results available

Evaluation of a Portable Oxygen Concentrator During Ambulation for Patients Who Require Supplemental Oxygen (POC-LEAN)

NCT04107493
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Portable Oxygen Cylinder, Mobi
Device
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 17, 2026, 11:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.

NCT00453687
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK233705
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 17, 2026, 11:16 PM EDT
Completed Phase 3 Interventional Results available

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

NCT02296138
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
olodaterol, tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
7,903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
117
States / cities
Andalusia, Alabama • Birmingham, Alabama • Florence, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 17, 2026, 11:16 PM EDT
Completed Not applicable Interventional Results available

Doxycycline for COPD in HIV-Infected Patients

NCT01744093
View directory record Official record
Conditions
HIV, Chronic Obstructive Pulmonary Disease (COPD), Emphysema
Interventions
Doxycycline, Placebo (sugar pill)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 17, 2026, 11:16 PM EDT
Completed Phase 4 Interventional Results available

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

NCT03265145
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Stiolto Respimat, ICS (Inhaled Corticosteroid) (Triple therapy), LABA (Long-Acting Beta Agonist) (Triple therapy), LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
90
States / cities
Mobile, Alabama • Montgomery, Alabama • Tucson, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 17, 2026, 11:16 PM EDT
Completed No phase listed Observational

ICS/LABA Adherence and COPD Exacerbation

NCT02446041
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Non-Interventional Study
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 17, 2026, 11:16 PM EDT
Completed Not applicable Interventional

Indoor Air Quality and Respiratory Symptoms in Former Smokers

NCT02956213
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
HEPA portable air filter, Sham Control/Active Comparator
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
40 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 17, 2026, 11:16 PM EDT